Rheumatoid arthritis: what is refractory disease and how to manage it?

Despite the enthusiastic progresses in the field of rheumatoid arthritis pharmacotherapy the presence of prognostic factors associated with an unfavorable outcome and the inappropriate and/or delayed initiation of DMARDs can diminish the likelihood of achieving remission and increase the probability of refractoriness to treatment. During the last decade we have experience exciting developments regarding the approval of new treatment options but few patients are reaching sustained remission and refractory patients continue to be a problem. Thus, it is critical to understand how clinicians can decrease the risk of refractoriness by close monitoring disease activity, using well defined and accepted composite measures, and by early and optimized use of DMARDs, including biologics. The goal of this review paper is to offer an evidence based roadmap to prevent and to deal with refractory RA.
AuthorsJoaquim Polido-Pereira, Elsa Vieira-Sousa, João Eurico Fonseca
JournalAutoimmunity reviews (Autoimmun Rev) Vol. 10 Issue 11 Pg. 707-13 (Sep 2011) ISSN: 1873-0183 [Electronic] Netherlands
PMID21570496 (Publication Type: Journal Article, Review)
CopyrightCrown Copyright © 2011. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Antirheumatic Agents
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Rheumatoid (diagnosis, drug therapy, physiopathology)
  • Disease Progression
  • Drug Resistance
  • Evidence-Based Medicine
  • Humans
  • Monitoring, Physiologic
  • Prognosis
  • Recurrence
  • Risk

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: